top of page



background 16.webp

ACTRIS was established on 20 April 2020 to meet the increasing clinical demand of using cellular therapeutics to treat various life-threatening diseases. ACTRIS’s vision is to be the national and regional Centre of Excellence for discovery, process development and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine, encompassing both investigational and approval products for the local market. ACTRIS aims to achieve accreditation from national and international regulators to ensure quality compliance of resource-efficient cellular therapy manufacturing. Our common goal is to promote and foster the entire value chain of the cellular therapy ecosystem through enabling translational research and development, manufacturing, clinical service provision and commercialisation by serving the healthcare, academic and industrial sectors. ACTRIS will also provide value-added services such as workforce training, regulatory facilitation and ancillary material standardization pertaining to delivery of cellular therapy to patients.

To learn more, go to

SingHealth Duke-NUS Cell Therapy (SDCT) Centre
Cell Therapy Center Logo Big Trans.png

SingHealth Duke-NUS Cell Therapy (SDCT) Centre is a virtual centre that brings together the strengths and expertise of healthcare professionals (Clinicians, Allied health professionals and Researchers) across various specialties in SingHealth institutions, to leverage on advanced cell and gene technologies to improve diagnostics, therapeutics, research and health outcomes by providing seamless, high-quality and holistic patient-centric care. Besides enhancing patient care, SDCT also focuses on formulating and coordinating cluster-wide Research and Development (R&D) activities pertaining to the development of novel cell and gene therapy products and associated technologies. SDCT aims to be a global leader in delivering CTGT products and technologies, with a vision to make regenerative medicine and cellular immunotherapy available to Singapore and the Asia-Pacific region.

To learn more, visit SDCT's website.

Singhealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS)
REMEDIS_Logo Transparent.png

Established in May 2021, Singhealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) was set up, to advance the efforts in regenerative medicine research by exploring the potential of regenerating diseased cells, tissue and even organs to develop research, regenerative therapies and tools to tackle age-related diseases and chronic conditions. Regenerative medicine is expected to have a significant impact in reducing the burden of age-related and chronic disease.

REMEDIS will focus efforts on 7 disease areas:

  • Musculoskeletal diseases

  • Bone marrow disorders

  • Blood disorders

  • Cardiovascular diseases

  • Acute and Chronic Wound Healing

  • Neuro-sensory diseases

  • Eye diseases


REMEDIS will work towards its vision of 'Restoring Function and Embracing Life' in collaboration with multidisciplinary research hubs and local clinical groups.

Follow REMEDIS and the developments of regenerative medicine here.

A*STAR Institute of Molecular and Cell Biology (IMCB)

A*STAR is a statutory board under the Ministry of Trade and Industry of Singapore. The agency supports R&D that is aligned to areas of competitive advantage and national needs for Singapore. These span the four technology domains of Manufacturing, Trade and Connectivity, Human Health and Potential, Urban Solutions and Sustainability, and Smart Nation and Digital Economy set out under the nation's five-year R&D plan (RIE2025). The agency's research institutes are located mostly in Biopolis and Fusionopolis. The total strength of the A*STAR community, including scientists and researchers, technical and non-technical staff, and industry development and commercialization staff was 5,400.




background 21.webp
In Partnership with
International Society for Cell & Gene Therapy (ISCT) 

Established in 1992, the International Society for Cell & Gene Therapy (ISCT) is a global society of clinicians, regulators, researchers, technologists, and industry partners with a shared vision to translate cell and gene therapy into safe and effective therapies to improve patients' lives worldwide.

ISCT is the global leader focused on pre-clinical and translational aspects of developing cell and gene-based therapeutics, thereby advancing scientific research into innovative treatments for patients. ISCT offers a unique collaborative environment that addresses three key areas of translation: Academia, Regulatory, and Commercialization. Through strong relationships with global regulatory agencies, academic institutions, and industry partners, ISCT drives the advancement of research into a standard of care.

Comprised of over 3,000 cell and gene therapy experts across five geographic regions and representation from over 60 countries, ISCT members are part of a global community of peers, thought leaders, and organizations invested in cell and gene therapy translation.

For more information about the organization, key initiatives and upcoming meetings, please visit:



background 16.webp
Diamond Sponsor
Thermo Fisher Scientific

As the world leader in serving science, Thermo Fisher Scientific is uniquely positioned to provide the quality materials, services and support need to accelerate the pace of cell and gene therapy development. We understand the complexity of this rapidly-evolving industry and have made significant investments in cGMP raw material manufacturing and drug product manufacturing capabilities to provide innovative workflow solutions. Partner with us to access the high-quality materials, services, and support you need from discovery to clinical research and commercial cell and gene manufacturing. Through our Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab services, Patheon, and Gibco brands, we offer an unmatched combination of innovative technologies, manufacturing, and distribution capabilities.

Platinum Sponsors
Miltenyi Biotec

Miltenyi Biotec is a global leader in innovating products and services that empower biomedical research and advance cellular therapy. The company's solutions support all stages of cell and gene therapy product development from process and analytical development to commercial-scale manufacturing. Its platform technologies have set industry standards in automated, integrated manufacturing and analysis of complex cellular products such as CAR-T cells, TCR-T cells, gene-modified NK and stem cells. Miltenyi Biotec’s comprehensive product portfolio is complemented by CDMO services for lentiviral vectors and cell manufacturing. The company has more than 4,700 employees in 23 countries and its products have been used in more than 100,000 cell therapy procedures.

Visit here for more information.


Advances in immunology and genetic engineering have led to the development of promising cellular therapeutics for the treatment of cancer, autoimmune diseases, and infectious diseases. However, developers of these complex "live" therapies are constantly challenged by scalability and high manufacturing costs.

Agilent's broad technology portfolio enables researchers and manufacturers to investigate the full range of cellular mechanisms of action, specificity, efficacy, phenotype, and fate. At every stage from discovery to process development, relevant critical quality attributes (CQAs) are identified to ensure that cellular products meet safety and efficacy criteria.


At Cytiva, our mission is to advance and accelerate the development of therapeutics. With nearly 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers.  Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers.

Visit to here read more.


Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial production, and commercial product manufacturing.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead acquired Kite in 2017.

background 20.png
Gold Sponsors
Fresenius Kabi


Bronze Sponsors

Lonza is propelling cell and gene therapy forward through its pioneering technologies and solutions. Our Nucleofector technology facilitates efficient and adaptable cell transfection, crucial for gene editing and therapy endeavours. Meanwhile, the Cocoon platform automates and refines cell therapy manufacturing, presenting a scalable, closed-system solution for personalized treatments. Lonza is committed to refining processes to hasten the development and production of these therapies. Our tailored services and top-notch facilities, equipped with scalable platforms and automated systems, bolster efficient manufacturing. Lonza's innovations expedite the journey from research to market, ultimately reducing costs and broadening patient access to state-of-the-art treatments.


Novartis is reimagining medicine to improve and extend people’s lives.  As a leading global healthcare company, it seeks to deliver transformative treatments by pushing the boundaries of medical paradigms and exploring possibilities to cure disease, intervening earlier in chronic illnesses and finding ways to exponentially enhance quality of life.

Having pioneered CAR T-cell therapy as an approved treatment for B-cell malignancies, Novartis remains committed to building on this innovation in CAR T-cell therapy and beyond, researching its CAR T-cell therapy in various clinical trials and constantly seeking new platforms to expand into new areas.

STEMCELL Technologies
Stemcell PNG.png

As a company of Scientists Helping Scientists, STEMCELL Technologies is committed to enabling cell and gene therapy research around the world with high-quality services and solutions. Whether you're editing CD34+ cells, differentiating PSCs, or expanding immune cells, we have over 2500 specialized cell isolation products, cell culture media, and reagents to help you get therapies to patients faster. Our ethically sourced human primary cell portfolio includes cryopreserved products from peripheral blood such as diseased PBMCs, cord blood, and bone marrow. Start your experiments with the right cells by exploring our range of primary and cultured cells.

Learn more here.


At the forefront of advancing therapeutic technologies, InnoCellular specializes in developing efficient and cost-effective cell culture media for stem cells and specialized cell applications. Renowned for our expertise, we excel in formulating high-performance, consistent, and top-quality biological products essential for pioneering next-generation therapies. Our services encompass a diverse array of options, from ready-to-use or basal formulations, designed for research-only or cGMP purposes, all tailored with unparalleled flexibility to meet your specific experimental or clinical needs.

To read more, visit here.


Singleron helps advance cell and gene therapy research by unravelling cellular heterogeneity. Our products and services aid researchers in identifying therapeutic targets, characterizing cell therapy products, tracking treatment outcomes, and revealing mechanisms for differential therapeutic responses. From tissue dissociation to specialized single cell multi-omic methods to advanced machine learning models, we have a solution that will meet your needs. As Singapore's longest-standing commercial single cell service provider, our expert team collaborates closely with you to ensure project success.

Choose Singleron for all your single cell analysis needs. Let us help accelerate your research and unlock its full potential, click here.

SGScmykcoated30mm - Copy_edited.png

With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products.

SGS provides a comprehensive range of biosafety services such as: virology, cell and molecular biology, microbiology and TEM. Health Authorities (US FDA and the EMA), require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses and other potential contaminants. SGS ensures product safety in satisfying these regulatory requirements.

Rapid Micro Biosystems

Rapid Micro Biosystems® (RMB) creates, sells, validates, and services innovative products for fast, accurate, and efficient detection of microbial contamination in the manufacture of cell and gene therapies, pharmaceuticals, biologics, biotechnology products, medical devices, and personal care products. The company’s Growth Direct® is the only fully automated, non-destructive growth-based system for multiple QC test applications: environmental monitoring, water, bioburden, and sterility testing. Automating rapid compendial QC micro testing ensures data integrity, compliance, and operational efficiencies. RMB is dedicated to providing groundbreaking technology and products to support companies in their journey to achieve greater reliability, efficiency, and better predictability, ultimately providing higher quality products for improved patient outcomes.

Academic & Start-up Sponsor
Accelerated Biosciences
AB Logo.png

Accelerated Biosciences (AB) represents a transformative approach in the healthcare sector, leveraging the groundbreaking potential of its human Trophoblast Stem Cells (hTSCs) to revolutionize cell and gene therapies as well as the creation of biosimilars. hTSCs is not just an advancement; it is a leap towards redefining healthcare possibilities. Originating from an ethical source, hTSCs represent a quantum leap in stem cell research. These cells possess the extraordinary ability to perform functions of many cell types, offering a practically limitless potential for medical applications. With the added genetic stability, natural immune privilege, and high expansion capacity, hTSCs are setting the stage for groundbreaking cell therapies. AB is actively engaging and collaborating with leading research institutes and biotech startup communities to translate this research into viable, life-changing treatments and products.

Powered by

AveLIVE logo new.png
bottom of page